Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment

Detalles Bibliográficos
Autores principales: Mukherjee, Shibani, Asaithamby, Aroumougame
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798592/
https://www.ncbi.nlm.nih.gov/pubmed/35117572
http://dx.doi.org/10.21037/tcr.2020.03.07
_version_ 1784641845326774272
author Mukherjee, Shibani
Asaithamby, Aroumougame
author_facet Mukherjee, Shibani
Asaithamby, Aroumougame
author_sort Mukherjee, Shibani
collection PubMed
description
format Online
Article
Text
id pubmed-8798592
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87985922022-02-02 Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment Mukherjee, Shibani Asaithamby, Aroumougame Transl Cancer Res Editorial Commentary AME Publishing Company 2020-04 /pmc/articles/PMC8798592/ /pubmed/35117572 http://dx.doi.org/10.21037/tcr.2020.03.07 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Mukherjee, Shibani
Asaithamby, Aroumougame
Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
title Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
title_full Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
title_fullStr Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
title_full_unstemmed Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
title_short Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
title_sort pancreatic cancer patients with germline brca mutations can benefit from olaparib treatment
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798592/
https://www.ncbi.nlm.nih.gov/pubmed/35117572
http://dx.doi.org/10.21037/tcr.2020.03.07
work_keys_str_mv AT mukherjeeshibani pancreaticcancerpatientswithgermlinebrcamutationscanbenefitfromolaparibtreatment
AT asaithambyaroumougame pancreaticcancerpatientswithgermlinebrcamutationscanbenefitfromolaparibtreatment

Ejemplares similares